English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) remains a serious global threat At the time of writing, there are no specific therapeutic agents or vaccines to combat this disease This study was designed to identify the SARS-CoV-2 main protease inhibitors using drug molecule information retrieved from DrugBank 5 0 (Wishart et al ) Methods: A set of common pharmacophores were generated from a series of 22 known SARS-CoV inhibitors The best pharmacophore used for virtual screening (VS) of DrugBank using the Phase module followed by structure-based virtual screening (VS) using Glide (Release 2020-1;Schrodinger LLC, New York, NY, USA) with SARS-CoV-2 main protease and 50 ns molecular dynamics (MD) simulation studies Results: Six hits were selected based on the fitness score, extra-precision Glide score, and binding affinity with the main protease (Mpro) The predicted inhibitor constant (Ki) values of the 3 best hits, DB03777, DB06834, and DB07456, were 0 8176, 0 2148, and 0 1006 mu M, respectively An MD simulation of DB07456 and DB13592 with the Mpro demonstrated stable protein-ligand complexes Conclusion: The selected inhibitors displayed a similar type of binding interaction with co-ligands and remdesivir, and the predicted Ki values of 2 inhibitors were found to be superior to remdesivir These selected hits may be used for further in vitro and in vivo studies against the SARS- CoV-2 Mpro

eurasian journal of medicine and oncology

In Silico Identification of Potential Inhibitors of the Main Protease of SERS-CoV-2 Using Combined Ligand-based and Structure-based Drug Design approach